DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism, Thromboembolism, Thrombosis, Embolism and Thrombosis, Deep Vein Thrombosis, Arthroplasty, Replacement, Hip
Trial Timeline
Jul 1, 2008 → Jun 1, 2009
NCT ID
NCT01203098About DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU) is a phase 2 stage product being developed by Daiichi Sankyo for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT01203098. Target conditions include Venous Thromboembolism, Thromboembolism, Thrombosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01203098 | Phase 2 | Completed |
Competing Products
20 competing products in Venous Thromboembolism